In addition, in human non-small cell lung cancer A549 cells with KRAS mutation, trametinib-mediated elevation of phosphorylated Akt was suppressed by fluvastatin (Figure 6C), and the co-treatment of both resulted in the increase of the sub-G1 population (Figure 6D). This evidence concerns the gene KRAS and non-small cell lung carcinoma.